US2016340414A1PendingUtilityA1
Rsv-specific antibodies and functional parts thereof
Est. expiryJan 15, 2034(~7.5 yrs left)· nominal 20-yr term from priority
A61P 31/12A61P 31/14C07K 16/11C07K 2317/90A61K 2039/505A61K 39/395C07K 2317/76C07K 2317/565C07K 2317/34C07K 2317/732C07K 16/1027
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
Claims
exact text as granted — not AI-modified1 . A synthetic or recombinant antibody or a functional part thereof capable of specifically binding Respiratory Syncytial Virus and comprising:
a. a heavy chain variable region CDR1 sequence comprising a sequence which is at least 70% identical to the sequence NYIIN (SEQ ID NO: 1) or DYIIN (SEQ ID NO: 9), and b. a heavy chain variable region CDR2 sequence comprising a sequence which is at least 75% identical to the sequence GIIPVLGTVHYAPKFQG (SEQ ID NO: 2) or GIIPVLGTVHYGPKFQG (SEQ ID NO: 10), and c. a heavy chain variable region CDR3 sequence comprising a sequence which is at least 70% identical to the sequence ETALVVSTTYLPHYFDN (SEQ ID NO: 3) or ETALVVSTTYRPHYFDN (SEQ ID NO: 11), and d. a light chain variable region CDR1 sequence comprising a sequence which is at least 85% identical to the sequence QASQDIVNYLN (SEQ ID NO: 4), and e. a light chain variable region CDR2 sequence comprising a sequence which is at least 70% identical to the sequence VASNLET (SEQ ID NO: 5), and f. a light chain variable region CDR3 sequence comprising a sequence which is at least 70% identical to the sequence QQYDNLP (SEQ ID NO: 6), and wherein at least one amino acid in the heavy chain differs from SEQ ID NO: 7 and said at least one amino acid is chosen from:
Position relative to SEQ ID NO: 7
Amino Acid
19
K
23
K
28
T or L
29
F
30
S or E
37
V
45
L
77
S
81
M
82
E or H
84
S
98
R.
2 . The antibody or functional part of claim 1 , wherein
a. heavy chain variable region CDR1 sequence comprises a sequence which differs by one amino acid from NYIIN (SEQ ID NO: 1) or DYIIN (SEQ ID NO: 9), b. heavy chain variable region CDR2 sequence comprises a sequence which differs by one or two amino acids from GIIPVLGTVHYAPKFQG (SEQ ID NO: 2) or GIIPVLGTVHYGPKFQG (SEQ ID NO: 10), c. heavy chain variable region CDR3 sequence comprises a sequence which differs by one or two amino acid from ETALVVSTTYLPHYFDN (SEQ ID NO: 3) or ETALVVSTTYRPHYFDN (SEQ ID NO: 11), d. light chain variable region CDR1 sequence comprises a sequence which differs by one amino acid from QASQDIVNYLN (SEQ ID NO: 4), e. light chain variable region CDR2 sequence comprises a sequence which differs by one amino acid from VASNLET (SEQ ID NO: 5), and/or f. light chain variable region CDR3 sequence comprises a sequence which differs by one amino acid from QQYDNLP (SEQ ID NO: 6).
3 . The antibody or functional part of claim 1 , wherein
a. heavy chain variable region CDR1 sequence comprises NYIIN (SEQ ID NO: 1) or DYIIN (SEQ ID NO: 9), b. heavy chain variable region CDR2 sequence comprises GIIPVLGTVHYAPKFQG (SEQ ID NO: 2) or GIIPVLGTVHYGPKFQG (SEQ ID NO: 10), c. heavy chain variable region CDR3 sequence comprises ETALVVSTTYLPHYFDN (SEQ ID NO: 3) or ETALVVSTTYRPHYFDN (SEQ ID NO: 11), d. light chain variable region CDR1 sequence comprises QASQDIVNYLN (SEQ ID NO: 4), e. light chain variable region CDR2 sequence comprises VASNLET (SEQ ID NO: 5), and f. light chain variable region CDR3 sequence comprises QQYDNLP (SEQ ID NO: 6).
4 . The antibody or functional part of claim 1 , wherein at least the following amino acids in the heavy chain variable region differ from SEQ ID NO: 7:
Position relative to SEQ ID NO: 7
Amino Acid
28
L
30
E
31
D
37
V
61
G
81
M
82
E
84
S.
5 . The antibody or functional part of claim 1 , wherein at least the following amino acids in the heavy chain variable region differ from SEQ ID NO: 7:
Position relative to SEQ ID NO: 7
Amino Acid
37
V
81
M
82
E
84
S.
6 . The antibody or functional part of claim 1 , wherein at least the following amino acids in the heavy chain variable region differ from SEQ ID NO: 7:
Position relative to SEQ ID NO: 7
Amino Acid
37
V
45
L
81
M
82
E
84
S.
7 . The antibody or functional part of any one of claim 1 , wherein at least the following amino acids in the heavy chain variable region differ from SEQ ID NO: 7:
Position relative to SEQ ID NO: 7
Amino Acid
19
K
23
K
28
T
29
F
30
S
37
V
45
L
81
M
82
E
84
S.
8 . The antibody or functional part of any one of claim 1 , wherein at least the following amino acids in the heavy chain variable region differ from SEQ ID NO: 7:
Position relative to SEQ ID NO: 7
Amino Acid
30
E
31
D
37
V
61
G
81
M
82
E
84
S.
9 . The antibody or functional part of claim 1 , wherein at least the following amino acids in the heavy chain variable region differ from SEQ ID NO: 7:
Position relative to SEQ ID NO: 7
Amino Acid
30
E
31
D
37
V
61
G
81
M
82
E
84
S
109
R.
10 . The antibody or functional part of claim 1 , wherein at least the following amino acids in the heavy chain variable region differ from SEQ ID NO: 7:
Position relative to SEQ ID NO: 7
Amino Acid
19
K
23
K
28
L
30
E
31
D
37
V
61
G
77
S
81
M
84
S
98
R.
11 . The antibody or functional part of claim 1 , wherein at least the following amino acids in the heavy chain variable region differ from SEQ ID NO: 7:
Position relative to SEQ ID NO: 7
Amino Acid
19
K
23
K
28
L
30
E
31
D
37
V
61
G
81
M
84
S.
12 . The antibody or functional part of claim 1 , wherein at least the following amino acids in the heavy chain variable region differ from SEQ ID NO: 7:
Position relative to SEQ ID NO: 7
Amino Acid
19
K
23
K
28
L
30
E
31
D
37
V
61
G
77
S
81
M
82
E
84
S.
13 . The antibody or functional part of claim 1 , wherein at least the following amino acids in the heavy chain variable region differ from SEQ ID NO: 7:
Position relative to SEQ ID NO: 7
Amino Acid
19
K
23
K
28
L
30
E
31
D
37
V
61
G
77
S
81
M
84
S.
14 . The antibody or functional part of claim 1 , wherein the heavy chain variable region is at least 90% identical to SEQ ID NO: 7 or SEQ ID NO: 13 and wherein the light chain variable region is at least 90% identical to SEQ ID NO: 8.
15 . The antibody or functional part of claim 14 , wherein the heavy chain variable region CDR1 sequence comprises a sequence which differs by one amino acid from either NYIIN (SEQ ID NO: 1) or DYIIN (SEQ ID NO: 9).
16 . The antibody or functional part of claim 14 , wherein the heavy chain variable region CDR2 sequence comprises a sequence which differs by one or two amino acids from GIIPVLGTVHYAPKFQG (SEQ ID NO: 2) or GIIPVLGTVHYGPKFQG (SEQ ID NO: 10).
17 . The antibody or functional part of claim 14 , wherein the heavy chain variable region CDR3 sequence comprising a sequence which differs by one or two amino acids from ETALVVSTTYLPHYFDN (SEQ ID NO: 3) or ETALVVSTTYRPHYFDN (SEQ ID NO: 11).
18 . The antibody or functional part of claim 14 , wherein the light chain variable region CDR1 sequence comprising a sequence which differs by one amino acid from QASQDIVNYLN (SEQ ID NO: 4).
19 . The antibody or functional part of any claim 14 , wherein the light chain variable region CDR2 sequence comprising a sequence which differs by one amino acid from VASNLET (SEQ ID NO: 5).
20 . The antibody or functional part of claim 14 , wherein the light chain variable region CDR3 comprises a sequence which differs by one amino acid from QQYDNLP (SEQ ID NO: 6).
21 . The antibody or functional part of claim 14 , wherein the heavy chain variable region CDR1 sequence comprises NYIIN (SEQ ID NO: 1) or DYIIN (SEQ ID NO: 9).
22 . The antibody or functional part of claim 14 , wherein the heavy chain variable region CDR2 sequence comprises GIIPVLGTVHYAPKFQG (SEQ ID NO: 2) or GIIPVLGTVHYGPKFQG (SEQ ID NO: 10).
23 . The antibody or functional part of claim 14 , wherein the heavy chain variable region CDR3 sequence comprises ETALVVSTTYLPHYFDN (SEQ ID NO: 3) or ETALVVSTTYRPHYFDN (SEQ ID NO: 11).
24 . The antibody or functional part of claim 14 , wherein the light chain variable region CDR1 sequence comprises QASQDIVNYLN (SEQ ID NO: 4).
25 . The antibody or functional part of claim 14 , wherein the light chain variable region CDR2 sequence comprises VASNLET (SEQ ID NO: 5).
26 . The antibody or functional part of claim 14 , wherein the light chain variable region CDR3 comprises QQYDNLP (SEQ ID NO: 6).
27 . The antibody or functional part of claim 1 , wherein the heavy chain variable region comprises a sequence which is 95% identical in the framework regions to a sequence chosen from SEQ ID NOs: 7 and 12-21.
28 . The antibody or functional part of claim 1 , wherein the heavy chain variable region comprises a sequence which is identical in the framework regions to a sequence chosen from SEQ ID NOs: 12-21.
29 . The antibody or functional part of claim 1 , wherein the heavy chain variable region comprises a sequence which is at least 70% identical to a sequence chosen from SEQ ID NOs: 12-21.
30 . The antibody or functional part claim 1 , having a light chain variable region sequence comprising a sequence which is at least 70% identical to SEQ ID NO: 8.
31 . The antibody or functional part of claim 1 , having a light chain sequence variable region comprising a sequence which is identical to SEQ ID NO: 8.
32 . A synthetic or recombinant antibody or a functional part thereof capable of specifically binding to a RSV F antigen and comprising:
a. a heavy chain variable region CDR1 sequence comprising the amino acid sequence DYIIN (SEQ ID NO: 9), and b. a heavy chain variable region CDR2 sequence comprising the amino acid sequence GIIPVLGTVHYGPKFQG (SEQ ID NO: 10), and c. a heavy chain variable region CDR3 sequence comprising the amino acid sequence ETALVVSTTYRPHYFDN (SEQ ID NO: 11), and d. a light chain variable region CDR1 sequence comprising the amino acid sequence QASQDIVNYLN (SEQ ID NO: 4), and e. a light chain variable region CDR2 sequence comprising the amino acid sequence VASNLET (SEQ ID NO: 5), and f. a light chain variable region CDR3 comprising the amino acid sequence QQYDNLP (SEQ ID NO: 6).
33 . A synthetic or recombinant antibody or a functional part thereof capable of specifically binding to a RSV F antigen and comprising:
a. a heavy chain variable region CDR1 sequence comprising the amino acid sequence DYIIN (SEQ ID NO: 9), and b. a heavy chain variable region CDR2 sequence comprising the amino acid sequence GIIPVLGTVHYGPKFQG (SEQ ID NO: 10), and c. a heavy chain variable region CDR3 sequence comprising the amino acid sequence ETALVVSTTYLPHYFDN (SEQ ID NO: 3), and d. a light chain variable region CDR1 sequence comprising the amino acid sequence QASQDIVNYLN (SEQ ID NO: 4), and e. a light chain variable region CDR2 sequence comprising the amino acid sequence VASNLET (SEQ ID NO: 5), and f. a light chain variable region CDR3 comprising the amino acid sequence QQYDNLP (SEQ ID NO: 6).
34 . The antibody or functional part of claim 1 , wherein the antibody or functional part is fully human, humanized antibody, or chimeric.
35 . The functional part of claim 1 , wherein the functional part is a single chain antibody, a single chain variable fragment (scFv), a Fab fragment, or a F(ab′) 2 fragment.
36 . The antibody or functional part of claim 1 , wherein the antibody or functional part has an IC50 of 5.0 ng/ml or less in a neutralization assay of RSV A2.
37 . The antibody or functional part of claim 1 , wherein the antibody or functional part has an IC50 or 3.0 ng/ml or less in a neutralization assay of RSV B9320.
38 . The antibody or functional part of claim 1 , wherein the antibody or functional part has an Fc region having Y at position 252Y, T at position 254T, and E at position 256, wherein the numbering corresponds to the EU index in Kabat.
39 . A method of inhibiting RSV infection in a subject comprising administering the antibody or functional part of claim 1 to the subj ect.
40 . The method of claim 39 , wherein the subject is a human patient.
41 . The method of claim 40 , wherein the subject is a human patient who was born prematurely.
42 . A synthetic, recombinant, or isolated nucleic acid sequence encoding the antibody or functional part of claim 1 .
43 . A method of inhibiting RSV infection in a subject comprising administering the nucleic acid of claim 42 to a subject.
44 . An isolated antibody producing cell capable of producing the antibody or functional part of claim 1 .
45 . The antibody producing cell according to claim 44 , which is stable for at least nine weeks.Join the waitlist — get patent alerts
Track US2016340414A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.